ALMS
Alumis Inc. Common Stock·Healthcare
21.33
4.478%(−1.00)
Close PriceLast Updated: — ET
52W L: $2.7652W H: $30.60
ALMS NEWS
fool.com
3d ago
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
fool.com
May 17
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
fool.com
May 15
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
globenewswire.com
May 14
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
fool.com
May 10
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
globenewswire.com
Mar 28
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
